Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

General

High-dose treatment with stem cell support (HDT with SCS) is intensive chemotherapy treatment used to kill cells in bone marrow. It is sometimes combined with total body irradiation to remove all cancer cells. The treatment causes life-threatening loss of blood-producing stem cells. Stem cells must therefore be harvested from the patient's blood/bone marrow before starting treatment. The stem cells are then transferred back to the patient after the high-dose treatment.

Indications

Standard treatment

  • Recurrence of non-Hodgkin lymphoma of cell types B or T, or where complete remission using first-line treatment is not achieved
  • Lymphoblastic lymphoma in first remission as an alternative to maintenance treatment with chemotherapy with conventional doses. 
  • Recurrence of Burkitt's lymphoma
  • Recurrence of B- and T-cell lymphoblastic lymphoma and in patients not previously undergoing HDT with SCS as primary treatment and where an allogeneic transplantation is not appropriate
  • Certain patients with recurrence of follicular lymphoma
  • Hodgkin's lymphoma with recurrence within two years after start of primary treatment including combination chemotherapy, with no response to primary treatment, other and later recurrences.
  • Certain patients with recurrence of transformed non-Hodgkin B-cell lymphoma.
  • Mantle cell lymphomas and peripheral T-cell lymphomas in first remission. 
  • Multiple myeloma: patients < 65 years of biological age.

Goal

  • Cure the disease
  • Prolong survival for patients with multiple myeloma

Oslo University Hospital shall not be liable for any loss whether direct, indirect, incidental or consequential, arising out of access to, use of, or reliance upon any of the content on this website. Oslo University Hospital© 2016